SALT LAKE CITY, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a leading molecular diagnostic company, today reported financial results for its first fiscal quarter ended September 30, 2010.
SALT LAKE CITY, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a leading molecular diagnostic company, today reported financial results for its first fiscal quarter ended September 30, 2010.